BR112018072450A2 - análogo de trifluoroetil quinolina específico para uso no tratamento de apds - Google Patents

análogo de trifluoroetil quinolina específico para uso no tratamento de apds

Info

Publication number
BR112018072450A2
BR112018072450A2 BR112018072450-5A BR112018072450A BR112018072450A2 BR 112018072450 A2 BR112018072450 A2 BR 112018072450A2 BR 112018072450 A BR112018072450 A BR 112018072450A BR 112018072450 A2 BR112018072450 A2 BR 112018072450A2
Authority
BR
Brazil
Prior art keywords
apds
trifluoroethyl
treatment
specific
quinoline analog
Prior art date
Application number
BR112018072450-5A
Other languages
English (en)
Inventor
Anthony Allen Rodger
John Armstrong Martin
CAVAZZANA Marina
KRACKER Sven
Philip MCHALE Duncan
Charles Payne Andrew
Original Assignee
Ucb Biopharma Sprl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ucb Biopharma Sprl filed Critical Ucb Biopharma Sprl
Publication of BR112018072450A2 publication Critical patent/BR112018072450A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

n-{(r)-1-[8-cloro-2-(1-oxipiridin-3-il)-quinolin-3-il]-2,2,2-trifluoroetil}-pirido[3,2-d]pirimidin-4-ilamina é efetiva no tratamento e/ou prevenção da síndrome da fosfoinositídeo 3-quinase delta ativada (apds).
BR112018072450-5A 2016-05-19 2017-05-15 análogo de trifluoroetil quinolina específico para uso no tratamento de apds BR112018072450A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1608797.5A GB201608797D0 (en) 2016-05-19 2016-05-19 Therapeutic use
GB1608797.5 2016-05-19
PCT/EP2017/061567 WO2017198590A1 (en) 2016-05-19 2017-05-15 A specific trifluoroethyl quinoline analogue for use in the treatment of apds

Publications (1)

Publication Number Publication Date
BR112018072450A2 true BR112018072450A2 (pt) 2019-02-19

Family

ID=56369612

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018072450-5A BR112018072450A2 (pt) 2016-05-19 2017-05-15 análogo de trifluoroetil quinolina específico para uso no tratamento de apds

Country Status (18)

Country Link
US (1) US20190209567A1 (pt)
EP (1) EP3458065A1 (pt)
JP (1) JP2019516703A (pt)
KR (1) KR20190009790A (pt)
CN (1) CN109152783A (pt)
AR (1) AR108500A1 (pt)
AU (1) AU2017267172A1 (pt)
BR (1) BR112018072450A2 (pt)
CA (1) CA3023974A1 (pt)
CL (1) CL2018003281A1 (pt)
CO (1) CO2018013559A2 (pt)
EA (1) EA201892638A1 (pt)
GB (1) GB201608797D0 (pt)
IL (1) IL262943A (pt)
MX (1) MX2018013770A (pt)
RU (1) RU2018144187A (pt)
SG (1) SG11201809396SA (pt)
WO (1) WO2017198590A1 (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3099693A4 (en) 2014-01-31 2017-08-16 Dana-Farber Cancer Institute, Inc. Uses of diazepane derivatives
CA2936865A1 (en) 2014-01-31 2015-08-06 Dana-Farber Cancer Institute, Inc. Diaminopyrimidine benzenesulfone derivatives and uses thereof
WO2017044849A1 (en) 2015-09-11 2017-03-16 Dana-Farber Cancer Institute, Inc. Cyano thienotriazolodiazepines and uses thereof
PE20181086A1 (es) 2015-09-11 2018-07-05 Dana Farber Cancer Inst Inc Acetamida tienotrizolodiazepinas y usos de las mismas
SG10201913450PA (en) 2015-11-25 2020-03-30 Dana Farber Cancer Inst Inc Bivalent bromodomain inhibitors and uses thereof
GB201708856D0 (en) 2017-06-02 2017-07-19 Ucb Biopharma Sprl Seletalisib crystalline forms

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR082799A1 (es) * 2010-09-08 2013-01-09 Ucb Pharma Sa Derivados de quinolina y quinoxalina como inhibidores de quinasa
JP2017516799A (ja) * 2014-05-27 2017-06-22 アルミラル・ソシエダッド・アノニマＡｌｍｉｒａｌｌ， Ｓ．Ａ． 医薬用途

Also Published As

Publication number Publication date
SG11201809396SA (en) 2018-11-29
IL262943A (en) 2018-12-31
EA201892638A1 (ru) 2019-06-28
CL2018003281A1 (es) 2019-01-25
RU2018144187A3 (pt) 2020-06-19
MX2018013770A (es) 2019-03-21
EP3458065A1 (en) 2019-03-27
WO2017198590A1 (en) 2017-11-23
JP2019516703A (ja) 2019-06-20
CO2018013559A2 (es) 2019-02-28
CA3023974A1 (en) 2017-11-23
AR108500A1 (es) 2018-08-29
AU2017267172A1 (en) 2018-12-13
KR20190009790A (ko) 2019-01-29
CN109152783A (zh) 2019-01-04
GB201608797D0 (en) 2016-07-06
US20190209567A1 (en) 2019-07-11
RU2018144187A (ru) 2020-06-19

Similar Documents

Publication Publication Date Title
BR112018072450A2 (pt) análogo de trifluoroetil quinolina específico para uso no tratamento de apds
BR112018014759A2 (pt) derivados de maitansinoide, conjugados dos mesmos e métodos de uso
BR112017020149A8 (pt) Derivados de maitansinoide, conjugados dos mesmos e métodos de uso
MA53881A (fr) Dérivés de pyrido[4,3-d][1,3]oxazin-2-one en tant qu'inhibiteurs de la forme mutée des protéines idh1 et idh2
CL2016002836A1 (es) Compuestos derivados de pirido pirimidin con actividad moduladora del empalme genico de smn2; composicion farmaceutica y uso en el tratamiento de la atrofia muscular espinal (ame).
BR112016024626A8 (pt) compostos 1h-pirrolo[2,3-c]piridin-7(6h)-onas e pirazolo[3,4-c]piridin-7(6h)-onas, uso dos mesmos, composição farmacêutica que os compreende e método de inibição de uma proteína bet
AU2015286723B2 (en) Influenza virus vaccines and uses thereof
WO2015160975A3 (en) Combination of a pi3k inhibitor with a bcl-2 inhibitor for use in the treatment of cancer
AU2015286721B2 (en) Influenza virus vaccines and uses thereof
EP4342545A3 (en) Viral prophylaxis treatment methods and pre-exposure prophylaxis kits
EP3474842A4 (en) COMPOSITIONS, DEVICES AND METHODS FOR THE TREATMENT OF ALCOHOL RELATED DISORDER
PH12016501371A1 (en) Pharmaceutical compositions comprising 15-hepe and methods of treating asthma and lung disorders using same
BR112018012927A2 (pt) reguladores cftr e métodos de uso dos mesmos
CL2016001104A1 (es) Preparación farmacéutica y método de su producción y uso.
PH12017501120A1 (en) Crosslinked polydiallymine copolymers for the treatment of type 2 diabetes
WO2014117010A3 (en) Composition for ophthalmic administration
BR112017020591B8 (pt) Uso de n-{(r)-1-[8-cloro-2-(1-oxipiridin-3-il)quinolin-3-il]-2,2,2-trifluoroetil}pirido[3,2-d]pirimidin-4-ilamina
MA40844A (fr) Compositions pharmaceutiques à action prolongée pour l'hépatite c
EP3432875A4 (en) FORMULATION AND METHOD FOR THE PREVENTION AND / OR TREATMENT OF SYMPTOMS OF WOOD HOLINESS
IT201700109607A1 (it) Composizione per l'uso nella prevenzione e/o nel trattamento del glaucoma.
HK1257288A1 (zh) Pi3k的活性或功能的抑制劑用於治療原發性舍格倫綜合征的用途
WO2020032902A3 (en) Aksolotl blastema for use in the treatment of wounds and burns
EP3389649A4 (en) CONNECTION FOR THE TREATMENT AND / OR PREVENTION OF PARASITISED DISEASES
UA115417U (xx) Спосіб профілактики та лікування гіпоксичних змін при карбоперитонеумі
TH1501004454B (th) สต๊อปเปอร์กำหนดตำแหน่งส่วนลำตัวยานพาหนะที่สูงขึ้น-ลดต่ำลงในส่วนช่วงล่างของยานยนต์

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI N? 10196/2001, QUE MODIFICOU A LEI N? 9279/96, A CONCESS?O DA PATENTE EST? CONDICIONADA ? ANU?NCIA PR?VIA DA ANVISA. CONSIDERANDO A APROVA??O DOS TERMOS DO PARECER N? 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL N? 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVID?NCIAS CAB?VEIS.

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06I Publication of requirement cancelled [chapter 6.9 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 6.6.1 NA RPI NO 2631 DE 08/06/2021 POR TER SIDO INDEVIDA.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements